RxDoctor Payments Data

Stephanie Swincher, APRN

Family · Louisville, KYNPI 1316275910

Payments from drug & device makers

$773in general payments, 2019–2025

Across 43 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shield Therapeutics Inc$161
  • Bayer$89
  • Novo Nordisk$68
  • Merck$49
  • Sanofi Pasteur Inc.$46
  • Gilead$46
  • plus $315 from 12 others

What the payments were for

  • Food & beverage$773100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Shield Therapeutics Inc7$161
Bayer5$89
Novo Nordisk4$68
Merck3$49
Sanofi Pasteur Inc.3$46
Gilead2$46
Astellas Pharma US Inc2$42
GSK3$41
Sanofi-aventis U.S. LLC2$36
Pfizer2$35
Cranial Technologies, Inc2$33
Lilly USA, LLC2$26
Nevro Corp.1$22
Hologic Sales And Service, LLC1$20
Exact Sciences1$17
VBI Vaccine (delaware) Inc.1$15
Amgen1$14
Cipher Pharmaceuticals US LLC1$14

How this compares

$773 in reported general payments places this provider in the 60th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$343
Medicare patients
26
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$61,436
JanuviaSitagliptin Phosphate73$53,561
XareltoRivaroxaban26$31,741
EliquisApixaban31$21,624
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$17,383
FarxigaDapagliflozin Propanediol15$12,880
RybelsusSemaglutide11$12,227
JardianceEmpagliflozin13$11,488
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$10,339
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$6,065
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,998
Potassium Chloride58$3,900
Ventolin HfaAlbuterol Sulfate43$3,039
Atorvastatin Calcium392$2,822
Albuterol Sulfate HfaAlbuterol Sulfate116$2,597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$68$73,66477 claims
MerckJanuvia$49$53,56173 claims
GSKTrelegy Ellipta, Anoro Ellipta$41$23,44834 claims
PfizerEliquis$35$21,62431 claims
Sanofi-aventis U.S. LLCLantus$36$72812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →